Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial

Yago Nieto¹, Pinaki Banerjee^{2

3}, Indreshpal Kaur², Rafet Basar^{2

3}, Ye Li^{2

3}, May Daher^{2

3}, Hind Rafei^{2

3}, Lucila N Kerbauy², Mecit Kaplan^{2

3}, David Marin^{2

3}, Lori Griffin², Melissa Barnett², Roland Bassett⁴, Nadima Uprety^{2

3}, Rejeena Shrestha^{2

3}, Francia Reyes Silva^{2

3}, Sanjida Islam^{2

3}, Christina Ganesh², Zephanie Borneo², Jeremy Ramdial², Alejandro Ramirez², Chitra Hosing², Amin Alousi², Uday Popat², Muzaffar Qazilbash², Sairah Ahmed⁵, Swaminathan Iyer⁵, Tania P Sainz⁶, Francisco Vega⁶, Natalie W Fowlkes⁷, Karenza Alexis⁸, Michael Emig⁸, Andreas Harstrick⁸, Andre Overesch⁸, Elizabeth J Shpall², Katayoun Rezvani^{2

3}

Affiliations

¹ Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ynieto@mdanderson.org.
² Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Institute for Cell Therapy Discovery and Innovation, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁵ Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁶ Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁷ Department of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁸ Affimed GmbH, Heidelberg, Germany.

Published Erratum

Yago Nieto et al. Nat Med. 2025 Aug.

. 2025 Aug;31(8):2816.

doi: 10.1038/s41591-025-03852-y.

¹ Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ynieto@mdanderson.org.
² Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Institute for Cell Therapy Discovery and Innovation, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁵ Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁶ Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁷ Department of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁸ Affimed GmbH, Heidelberg, Germany.

No abstract available

Erratum for

Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial.
Nieto Y, Banerjee P, Kaur I, Basar R, Li Y, Daher M, Rafei H, Kerbauy LN, Kaplan M, Marin D, Griffin L, Barnett M, Bassett R, Uprety N, Shrestha R, Silva FR, Islam S, Ganesh C, Borneo Z, Ramdial J, Ramirez A, Hosing C, Alousi A, Popat U, Qazilbash M, Ahmed S, Iyer S, Sainz TP, Vega F, Fowlkes NW, Alexis K, Emig M, Harstrick A, Overesch A, Shpall EJ, Rezvani K. Nieto Y, et al. Nat Med. 2025 Jun;31(6):1987-1993. doi: 10.1038/s41591-025-03640-8. Epub 2025 Apr 4. Nat Med. 2025. PMID: 40186077 Clinical Trial.